Amedisys (NASDAQ:AMED) Issues Quarterly Earnings Results

Amedisys (NASDAQ:AMED) posted its earnings results on Wednesday. The health services provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01, Briefing.com reports. Amedisys had a negative net margin of 0.91% and a positive return on equity of 13.00%. The firm had revenue of $571.41 million during the quarter, compared to the consensus estimate of $565.38 million. During the same period last year, the firm posted $1.00 EPS. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis.

Amedisys Stock Performance

Shares of AMED traded up $0.58 during midday trading on Friday, hitting $91.74. 47,485 shares of the stock traded hands, compared to its average volume of 274,985. Amedisys has a 1-year low of $73.10 and a 1-year high of $96.44. The firm has a market capitalization of $3.00 billion, a PE ratio of -142.84, a price-to-earnings-growth ratio of 4.28 and a beta of 0.86. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.05 and a current ratio of 1.05. The business’s 50 day moving average price is $92.57 and its two-hundred day moving average price is $93.35.

Wall Street Analyst Weigh In

Several research firms have issued reports on AMED. StockNews.com began coverage on shares of Amedisys in a research note on Monday, April 8th. They set a “buy” rating on the stock. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 target price on shares of Amedisys in a research report on Thursday. Royal Bank of Canada raised their price target on shares of Amedisys from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 25th. Finally, Raymond James reiterated a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. Seven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $97.50.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.